Search - tctmd.com

Displaying 21 - 40 of 66

Sort: Relevancy | Date

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

News Daily News

Worse Complications After PVI in Women Highlight Research Gaps

L.A. McKeown

August 16, 2022

News Opinion CV Team Dispatch

August 2022 News Roundup

L.A. McKeown

August 01, 2022

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

L.A. McKeown

June 29, 2022

News Opinion CV Team Dispatch

February 2022 News Roundup

L.A. McKeown

February 01, 2022

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

L.A. McKeown

August 10, 2021

News Daily News

PAD Continues to Elude Clinicians, Despite Gains: AHA

L.A. McKeown

August 05, 2021

News Opinion CV Team Dispatch

June 2021 News Roundup

L.A. McKeown

June 01, 2021

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

L.A. McKeown

May 21, 2021

News Features

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

L.A. McKeown

December 24, 2020

News Daily News

‘Frailty Meter’ May Aid Treatment Decisions in Chronic Limb-Threatening Ischemia

L.A. McKeown

November 24, 2020

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

L.A. McKeown

September 03, 2020

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

L.A. McKeown

August 12, 2020

News Daily News

PAD Patients Undertreated With Statins Despite Elevated CV Risk

L.A. McKeown

July 13, 2020

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

L.A. McKeown

March 28, 2020

News Daily News

Outcome Differences Between Men and Women With PAD: EUCLID Insights

L.A. McKeown

February 11, 2020

News Daily News

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

L.A. McKeown

September 16, 2019

Advertisement

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

Worse Complications After PVI in Women Highlight Research Gaps

August 2022 News Roundup

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

February 2022 News Roundup

December 2021 News Roundup

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

PAD Continues to Elude Clinicians, Despite Gains: AHA

June 2021 News Roundup

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

‘Frailty Meter’ May Aid Treatment Decisions in Chronic Limb-Threatening Ischemia

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

PAD Patients Undertreated With Statins Despite Elevated CV Risk

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

Outcome Differences Between Men and Women With PAD: EUCLID Insights

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content